These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 20196739)
21. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475 [TBL] [Abstract][Full Text] [Related]
22. HDL subfractions analysis: a new laboratory diagnostic assay for patients with cardiovascular diseases and dyslipoproteinemia. Oravec S; Dostal E; Dukát A; Gavorník P; Kucera M; Gruber K Neuro Endocrinol Lett; 2011; 32(4):502-9. PubMed ID: 21876506 [TBL] [Abstract][Full Text] [Related]
23. Clinical review: The evolving role of HDL in the treatment of high-risk patients with cardiovascular disease. Brewer HB J Clin Endocrinol Metab; 2011 May; 96(5):1246-57. PubMed ID: 21389140 [TBL] [Abstract][Full Text] [Related]
24. Exercise-mediated changes in high-density lipoprotein: impact on form and function. Blazek A; Rutsky J; Osei K; Maiseyeu A; Rajagopalan S Am Heart J; 2013 Sep; 166(3):392-400. PubMed ID: 24016485 [TBL] [Abstract][Full Text] [Related]
25. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Otvos JD; Collins D; Freedman DS; Shalaurova I; Schaefer EJ; McNamara JR; Bloomfield HE; Robins SJ Circulation; 2006 Mar; 113(12):1556-63. PubMed ID: 16534013 [TBL] [Abstract][Full Text] [Related]
26. Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial. Albers JJ; Slee A; Fleg JL; O'Brien KD; Marcovina SM Atherosclerosis; 2016 Aug; 251():454-459. PubMed ID: 27320173 [TBL] [Abstract][Full Text] [Related]
27. High-Density Lipoprotein Subclasses and Noncardiovascular, Noncancer Chronic Inflammatory-Related Events Versus Cardiovascular Events: The Multi-Ethnic Study of Atherosclerosis. Duprez DA; Otvos J; Tracy RP; Feingold KR; Greenland P; Gross MD; Lima JA; Mackey RH; Neaton JD; Sanchez OA; Jacobs DR J Am Heart Assoc; 2015 Sep; 4(9):e002295. PubMed ID: 26370448 [TBL] [Abstract][Full Text] [Related]
28. Polyacrylamide gradient gel electrophoresis of lipoprotein subclasses. Warnick GR; McNamara JR; Boggess CN; Clendenen F; Williams PT; Landolt CC Clin Lab Med; 2006 Dec; 26(4):803-46. PubMed ID: 17110241 [TBL] [Abstract][Full Text] [Related]
29. Relationship between plasma HDL subclasses distribution and lipoprotein lipase gene HindIII polymorphism in hyperlipidemia. Long S; Tian Y; Zhang R; Yang L; Xu Y; Jia L; Fu M Clin Chim Acta; 2006 Apr; 366(1-2):316-21. PubMed ID: 16364275 [TBL] [Abstract][Full Text] [Related]
30. Emerging role of high-density lipoprotein in the prevention of cardiovascular disease. Brousseau ME Drug Discov Today; 2005 Aug; 10(16):1095-101. PubMed ID: 16182194 [TBL] [Abstract][Full Text] [Related]
31. Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein. Kon V; Yang H; Fazio S Arch Med Res; 2015 Jul; 46(5):379-91. PubMed ID: 26009251 [TBL] [Abstract][Full Text] [Related]
32. HDL and cardiovascular disease. Nicholls SJ; Nelson AJ Pathology; 2019 Feb; 51(2):142-147. PubMed ID: 30612759 [TBL] [Abstract][Full Text] [Related]
34. Separation of three compositionally distinct subclasses of rat high density lipoproteins by heparin-affinity chromatography. Lee CC; Koo SI Atherosclerosis; 1988 Apr; 70(3):205-15. PubMed ID: 3365289 [TBL] [Abstract][Full Text] [Related]
35. Optical Properties of Europium Tetracycline Complexes in the Presence of High-Density Lipoproteins (HDL) Subfractions. Sicchieri LB; Monteiro AM; Figueiredo Neto AM; Gomes L; Courrol LC Appl Spectrosc; 2017 Jul; 71(7):1560-1567. PubMed ID: 27956595 [TBL] [Abstract][Full Text] [Related]
36. Effect of ezetimibe on low- and high-density lipoprotein subclasses in sitosterolemia. Othman RA; Myrie SB; Mymin D; Roullet JB; Steiner RD; Jones PJH Atherosclerosis; 2017 May; 260():27-33. PubMed ID: 28340366 [TBL] [Abstract][Full Text] [Related]
37. High-density lipoprotein-mediated anti-atherosclerotic and endothelial-protective effects: a potential novel therapeutic target in cardiovascular disease. Besler C; Heinrich K; Riwanto M; Lüscher TF; Landmesser U Curr Pharm Des; 2010 May; 16(13):1480-93. PubMed ID: 20196740 [TBL] [Abstract][Full Text] [Related]
38. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial. Mora S; Caulfield MP; Wohlgemuth J; Chen Z; Superko HR; Rowland CM; Glynn RJ; Ridker PM; Krauss RM Circulation; 2015 Dec; 132(23):2220-9. PubMed ID: 26408274 [TBL] [Abstract][Full Text] [Related]